Table 1.
Demographic and baseline (prior to initiation of favipiravir) characteristics of patients.
| Characteristics | n = 40 (%) |
|---|---|
| Age groups | |
| ≤50 year | 12 (30) |
| 50 to < 70 year | 22 (55) |
| ≥70 year | 6 (15) |
| Sex | |
| Male | 23 (58) |
| Female | 17 (42) |
| Health care workers | 6 (15) |
| Underlying medical conditions | 25 (63) (at least one) |
| Hypertension | 12 (30) |
| Diabetes mellitus | 11 (28) |
| Coronary artery disease | 5 (13) |
| Malignancy | 3 (8) |
| Hypothyroidism | 3 (8) |
| Asthma | 2 (5) |
| Contact with confirmedCOVID-19 infection | 17 (43) |
| Signs and symptoms | |
| Fever | 34 (85) |
| Cough | 29 (73) |
| Dyspnoea | 15 (38) |
| Sore throat | 11 (28) |
| Fatigue | 10 (25) |
| Sputum production | 7 (18) |
| Diarrhea | 7 (18) |
| Oxygen support status at baseline | |
| Face mask | 19 (47.5) |
| Ambient air | 10 (25) |
| CPAP | 7 (17.5) |
| Mechanical ventilation | 4 (10) |
| Need for inotropes or vasopressors during favipiravir treatment | 4 (10) |